CB2 cannabinoid receptor-mediated peripheral antinociception

Pain

Volumn 93, Issue 3, 2001, Pages 239-245

  Malan Jr , T Philip ^a   Ibrahim, Mohab M ^a   Deng, Hongfeng ^b   Liu, Qian ^b   Mata, Heriberto P ^a   Vanderah, Todd ^a   Porreca, Frank ^a   Makriyannis, Alexandros ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antagonists; Cannabinoid receptor; CB1 receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AM 1421; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANALGESIC AGENT; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR CB2, RAT; DRUG RECEPTOR; INDOLE DERIVATIVE; IODOPRAVADOLINE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GAIT DISORDER; HYPOTHERMIA; IMMOBILIZATION; INJECTION SITE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; STIMULUS RESPONSE; THERMAL STIMULATION; ANIMAL; DRUG POTENTIATION; METABOLISM; PAIN ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; CANNABINOIDS; INDOLES; MALE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0034886018     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(01)00321-9     Document Type: Article

References (39)

1. Control of pain initiation by endogenous cannabinoids
2. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
3. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
4. 123I-labelled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid receptors
5. Binding of the non-classical cannabinoid CP55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors
6. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals
7. Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: Further evidence of cannabinoid CB2 receptor absence in the rat central nervous system
8. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor
9. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
10. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
11. + channels
12. Cannabinoid receptors undergo axonal flow in sensory nerves
13. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of dorsal root ganglia: A double-label in situ hybridization study
14. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2
15. Role of adenylate cyclase in immunologic release of mediators from mast cells: Agonist and antagonist effects or purine- and ribose-modified adenosine analogs
16. 35S]GTP -S binding in the mouse brain
17. Supression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G protein-coupled mechanism
18. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimemetic?
19. Spinal and supraspinal components of cannabinoid-induced antinociception
20. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement
21. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
22. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
23. Antinociceptive actions of cannabinoids following intraventricular administration in rats
24. An examination of the central sites of action on cannabinoid -induced antinociception in the rat
25. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects
26. Endocannabinoids
27. Molecular characterization of a peripheral receptor for cannabinoids
28. Pharmacology of cannabinoid CB1 and CB2 receptors
29. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurons and for the existence of neuronal non-CB1 cannabinoid receptors
30. Cannabinoids modulate pain by multiple mechanisms of action
31. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
32. Antihyperalgesic effects of spinal cannabinoids
33. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia
34. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630
35. Delta 9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function
36. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands
37. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat
38. Ethical guidelines for investigations of experimental pain in conscious animals